Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Crescent Biopharma, Inc. publishes a filing, an earnings call transcript or a press release.

Get CBIO alerts

About Harout Semerjian

Harout Semerjian is recorded as Board Member and CEO at Crescent Biopharma, Inc. (CBIO) since August 6, 2021. Crescent Biopharma, Inc. reported in an 8-K filed February 25, 2025 that Harout Semerjian resigned as Chief Executive Officer, effective February 21, 2025. The same filing states: “None of the individual decisions were a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.” Crescent Biopharma, Inc. reported in an 8-K filed February 25, 2025 that Harout Semerjian resigned as Board of Directors, effective February 21, 2025. The same filing states: “None of the individual decisions were a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.” Crescent Biopharma, Inc. reported in an 8-K filed August 5, 2021 that Harout Semerjian was appointed Director, effective August 6, 2021. Equibles holds 4 filed executive changes naming Harout Semerjian; each is listed under recent activity with its source filing. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Crescent Biopharma, Inc. includes Joshua Brumm (CEO and Board Member), Peter Harwin (Chairman and Board Member), Richard Scalzo (CFO) and 7 others.

“each of Mr. Harout Semerjian, the Chief Executive Officer of the Company and Mr. Brian Hahn, the Company's Chief Financial Officer, ceased his respective employment with the Company as of February 21, 2025 (the "Separation Date").”
“None of the individual decisions were a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Crescent Biopharma, Inc. Form 8-K, filed February 25, 2025 · Read the filing
“Pursuant to the Separation Agreement described below, Mr. Semerjian also resigned from the Board of Directors effective as of February 21, 2025.”
“None of the individual decisions were a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Crescent Biopharma, Inc. Form 8-K, filed February 25, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Crescent Biopharma, Inc.

Recent activity